DOCSLIB.ORG

1 Effective August 1, 2021

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
1 Effective August 1, 2021 Effective August 1, 2021 - PROVIDER COPY THIS LIST APPLIES TO ALL MEDICARE MEMBERS Certain drugs require prior authorization in order to be covered under your health plan. Prior authorization review is the process of determining the medical necessity of a proposed procedure, surgery or treatment (including prescribed drug intervention) relative to approved criteria. Prior authorization is required to ensure that the drug is medically necessary and you will receive the benefits to which you are entitled. Requests for prior authorization must be received before the services or drugs are provided/ administered. Failure of a network provider to contact SummaCare for required authorization of items covered under your benefit plan will relieve the health plan and you from any financial responsibility for the service if those services are rendered before notifying the plan. NOTE: Network providers are responsible for obtaining authorization at least 48 hours before administering these prescription drugs. If the provider is not in the plan network, it is the member’s responsibility to verify that prior authorization has been obtained. How to request prior authorization for drugs covered under the medical benefit: • Fax submission of requests for prior authorization should be used for non-urgent requests. • Routine requests: Fax 234-231-7082 • Urgent requests: Call 330-996-8710 or 888-996-8710 • Oncology requests: For all drugs marked with “*” Call 855-774-1315 SummaCare provides coverage under the medical benefit for many drugs that are administered in an office, home or outpatient setting. We require certain drugs to receive prior authorization before being administered. The following drugs may require prior authorization: PROVIDER COPY 5FU (fluorouracil) * ALKERAN (melphalan) * ABRAXANE (paclitaxel) * ALOXI (palonosetron) * ACTEMRA (tocilizumab) * ALPHANATE (antihemophilic factor) ACTHAR GEL (corticotropin) ALPHANINE SD (antihemophilic factor) ACTIMMUNE (interferon gamma-1b) * ALPROLIX (factor product) ADAKVEO (crizanlizumab-tmca) AMONDYS (casimersen) ADCETRIS (brentuximab vedotin) * ANDEXXA (andexanet alfa) ADRIAMYCIN (doxorubicin) * ARA-C (cytarabine) * ADVATE (factor product) ARALAST (alpha proteinase inhibitor) ADYNOVATE (antihemophilic factor VIII) ARANESP (darbepoetin alfa) * AFSTYLA (factor product) AREDIA (pamidronate disodium) * AKYNZEO (fosnetupitant/palonosetron) * ARRANON (nelarabine) * ALIMTA (premetrexed disodium) * ARZERRA (ofatumumab) * ALIQOPA (copsnlidib)* ASCENIV (immune globulin) 1 ASPARLAS (calaspargase pegol-mknl) * DANYELZA (naxitamab-gqgk) * ATGAM (antithymocyte globulin) DARZALEX (daratumumab) * AVASTIN (bevacizumab) * DARZALEX FASPRO (daratumumab-hyaluronidase) * AVONEX (interferon beta-1a) DEPOCYT (cytarabine-liposome) * AVSOLA (infliximab-axxq) DOJOLVI (triheptanoin) AZEDRA (iobenguane I 131) DOXIL (doxorubicin-liposome) * BAVENCIO (avelumab) * DTIC-DOME (dacarbazine) * BCNU (carmustine) * DUROLANE (hyaluronate and derivatives) BEBULIN/BEBULIN VH (factor product) DYSPORT (abobotulinumtoxin A) BELEODAQ (belinostat) * ELELYSO (taliglucerase–alfa) BELRAPZO (bendamustine) * ELIGARD (leuprolide acetate) * BENDEKA (bendamustine) * ELLENCE (epirubicin) * BENEFIX (factor product) ELOCTATE (factor product) BENLYSTA IV (belimumab) ELOXATIN (oxaliplatin) * BERINERT (c1 esterase inhibitor) ELZONRIS (tagraxofusp-erzs) * BESPONSA (inotuzumab ozogamicin) * EMPLICITI (elotuzumab) * BIVIGAM (immune globulin) EMPAVELI (pegcetacoplan) BLENOXANE (bleomycin) * ENHERTU (fam-trastuzumab deruxtecan-nxki) * BLENREP (belantamab mafodotin-blmf) * ENTYVIO (vedolizumab) BLINCYTO (blinatumomab) * EPOGEN (epoetin alfa) * BOTOX (onabotulinumtoxin A) ERBITUX (cetuximab) * BRINEURA (cerliponase alfa) ERWINAZE (asparaginase) * CABLIVI (caplacizumab-yhdp) ESPEROCT (factor product) CAMPTOSAR (irinotecan) * EVENITY (romosozumab-aqqg) CARIMUNE (immune globulin) EVKEEZA (evinacumab-dgnb) CAYSTON (aztreonam for inhalation) EVOMELA (melphalan) * CERUBIDINE (daunorubicin) * EXONDYS 51 (eteplirsen) CIMZIA (certolizumab pegol) FASENRA (benralizumab) CINQAIR (reslizumab) FASLODEX (fulvestrant) * CINRYZE (c1 esterase inhibitor) FEIBA NF (factor product) CINVANTI (aprepitant) * FENSOLVI (leuprolide acetate) * CLOLAR (clofarabine) * FIRMAGON (degarelix) * COAGADEX (factor product) FLEBOGAMMA (immune globulin) CORIFACT (factor product) FLOLAN (epoprostenol sodium) COSELA (trilaciclib) * FLUDARA (fludarabine) * COSMEGEN (dactinomycin) * FOLOTYN (pralatrexate) * CRYSVITA (burosumab-twza) FUDR (floxuridine) * CUVITRU (immune globulin) FULPHILA (pegfilgrastim-jmdb) * CYRAMZA (ramucirumab) * FUSILEV (levoleucovorin) * CYTOGAM (cytomegalovirus immune globulin) GAMASTAN (immune globulin) CYTOXAN (cyclophosphamide) * GAMIFANT (emapalumab-lzsg) DACOGEN (decitabine) * GAMMAGARD (immune globulin) 2 GAMMAPLEX (immune globulin) KADCYLA (trastuzumab emtansine) * GAMMAKED (immune globulin) KANJINTI (trastuzumab-anns) * GAMUNEX-C (immune globulin) KANUMA (sebelipase alfa) GAZYVA (obinutuzumab) * KCENTRA (factor product) GEL-ONE (hyaluronate and derivatives) KEYTRUDA (pembrolizumab) * GELSYN (hyaluronate and derivatives) KHAPZORY (levoleucovorin) * GENVISC (hyaluronate and derivatives) KOATE (factor product) GEMZAR (gemcitabine) * KOGENATE FS (factor product) GIVLAARI (givosiran) KOVALTRY (factor product) GLASSIA (proteinase inhibitor) KRYSTEXXA (pegloticase) GRANIX (tbo-filgrastim) * KYMRIAH (tisagenleceucel) HAEGARDA (c1 esterase inhibitor - human) KYPROLIS (carfilzomib) * HALAVEN (eribulin mesylate) * LARTRUVO (olaratumab) * HELIXATE FS (factor product) LEMTRADA (alemtuzumab) HEMLIBRA (emicizumab-kxwh) LEUCOVORIN * HEMOFIL M (antihemophilic factor) LEUKINE (sargramostim) * HERCEPTIN (trastuzumab) * LEUSTATIN (cladribine) * HERCEPTIN HYLECTA (trastuzumab, 10 mg and LIBTAYO (cemiplimab-rwic) * Hyaluronidase-oysk) * HERZUMA (trastuzumab-pkrb) * LUMIZYME (alglucosidase) HIZENTRA (immune globulin) LUMOXITI (moxetumomab psaudotox-tdfk) * HUMATE-P (factor product) LUPRON DEPOT (leuprolide acetate) * HYALGAN (hyaluronate and derivatives) LUTATHERA (lutetium lu177 dotatate) HYCAMTIN (topotecan) * LUXTURNA (voretigene neparvovec-rzyl) HYMOVIS (hyaluronate and derivatives) MARGENZA (margetuximab) HYQVIA (immune globulin) MARQIBO (vincristine sulfate liposome) * IDAMYCIN (idarubicin) * MEPSEVII (vestronidase alfa-vjbk) IDELVION (factor product) MESNEX (mesna) * IFEX (ifosfamide) * METHOTREXATE * ILARIS (canakinumab) MIRCERA (methoxy polyethylene glycol-epoetin beta) ILUMYA (tildrakizumab-asmn) MONJUVI (tafasitamb-cxix) * IMFINZI (durvalumab) * MONOCLATE-P (factor product) IMLYGIC (talimogene laherparepvec) * MONONINE (factor product) INFLECTRA (infliximab-dyyb) MONOVISC (hyaluronate and derivatives) INFUGEM (gemcitabine) * MUSTRAGEN (mechlorethamine) * INTRON A (interferon alfa-2b) * MUTAMYCIN (mitomycin) * ISTODAX (romidepsin) * MVASI (bevacizumab-awwb) * IXEMPRA (ixabepilone) * MYLOTARG (gemtuzumab ozogamicin) * IXINITY (factor product) MYOBLOC (rimabotulinumtoxin b) JELMYTO (mitomycin)* NAVELBINE (vinorelbine) * JEMPERLI (dostarlimab-gxly) * NEULASTA (pegfilgrastim) * JEVTANA (cabazitaxel) * NEUPOGEN (filgrastim) * JIVI (factor product) NIPENT (pentostatin) * 3 NIVESTYM (filgrastim-aafi) * PROLASTIN C (alpha proteinase inhibitor) NOVANTRONE (mitoxantrone) * PROLEUKIN (aldesleukin) * NOVOEIGHT (factor product) PROVENGE (sipuleucel-T) * NOVOSEVEN RT (factor product) QUTENZA (capsaicin 8% patch) NPLATE (romiplostim) QUZYTTIR (cetirizine hcl) NUCALA (mepolizumab) RADICAVA (edaravone) NULOJIX (belatacept) REBINYN (factor product) NUWIQ (factor product) REBLOZYL (luspatercept-aamt) * NYVEPRIA (pegfilgrastim-apgf) * RECOMBINATE (factor product) OBIZUR (antihemophilic factor) RELISTOR (methylnaltrexone bromide) OCREVUS (ocrelizumab) REMICADE (infliximab) OCTAGAM (immune globulin) REMODULIN (treprostinil) OFIRMEV (acetaminophen injection) RENFLEXIS (infliximab-abda) OGIVRI (Trastuzumab-dkst) * REPATHA (evolocumab) ONCASPAR (pegaspargase) * RETACRIT (epoetin alfa) * ONCOVIN (vincristine sulfate) * RIABNI (rituximab-arrx) * ONIVYDE (irinotecan liposome) * RITUXAN (rituximab) * ONPATTRO (patisiran) RITUXIN HYCELA (rituximab-hyaluronidase human) * ONTRUZANT (trastuzumab-dttb) * RIXUBIS (factor product) OPDIVO (nivolumab) * RUCONEST (c1 esterase inhibitor) ORENCIA (abatacept) RUXIENCE (rituximab-pvvr) * ORTHOVISC (hyaluronate and derivatives) RYBREVANT (amivantamab-vmjw) * OXLUMO (lumasiran) SANDOSTATIN (octreotide) * PADCEV (enfortumab vedotin-ejfv) * SARCLISA (isatuximab-irfc) * PANZYGA (immune globulin-ifas) SCENESSE (afamelanotide) PARAPLATIN (carboplatin) * SEVENFACT (factor product) PARSABIV (etelcalcetide) SIGNIFOR LAR (pasireotide pamoate) PEGASYS (peginterferon alfa-2a) * SIMPONI ARIA (golimumab) PEGINTRON (peginterferon alfa-2b) * SOLIRIS (eculizumab) PEPAXTO (melphalan flufenamide) * SOMATULINE DEPOT (lanreotide) * PERJETA (pertuzumab) * SPINRAZA (nusinersen) PHESGO (pertuzumab, trastuzumab, hyaluronidase) * SPRAVATO (esketamine) PHOTOFRIN (porfimer) * STELARA (ustekinumab) PLATINOL (cisplatin) * STRENSIQ (asfotase alfa) POLIVY (polatuzumab vedotin-piiq) * SUPARTZ FX (hyaluronate and derivatives) PORTRAZZA (necitumumab) * SUSTOL (granisetron) * POTELIGEO (mogamulizumab-kpkc) * SYLATRON (peginterferon, alfa-2b) * PRALUENT (alirocumab) SYLVANT (siltuximab) * PRIVIGEN (immune globulin) SYNAGIS (palivizumab) PROBUPHINE IMPLANT (buprenorphine) SYNRIBO (omacetaxine mepesuccinate) * PROCRIT (epoetin alfa) * SYNVISC (hyaluronate and derivatives) PROFILNINE SD (factor product) SYNVISC-ONE
Load more

Recommended publications
  • Minutes of the CHMP Meeting 14-17 September 2020
    13 January 2021 EMA/CHMP/625456/2020 Corr.1 Human Medicines Division Committee for medicinal products for human use (CHMP) Minutes for the meeting on 14-17 September 2020 Chair: Harald Enzmann – Vice-Chair: Bruno Sepodes Disclaimers Some of the information contained in these minutes is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also vary during the course of the review. Additional details on some of these procedures will be published in the CHMP meeting highlights once the procedures are finalised and start of referrals will also be available. Of note, these minutes are a working document primarily designed for CHMP members and the work the Committee undertakes. Note on access to documents Some documents mentioned in the minutes cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to on- going procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006). 1 Addition of the list of participants Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 An agency of the European Union © European Medicines Agency, 2020.
    [Show full text]
  • Predictive QSAR Tools to Aid in Early Process Development of Monoclonal Antibodies
    Predictive QSAR tools to aid in early process development of monoclonal antibodies John Micael Andreas Karlberg Published work submitted to Newcastle University for the degree of Doctor of Philosophy in the School of Engineering November 2019 Abstract Monoclonal antibodies (mAbs) have become one of the fastest growing markets for diagnostic and therapeutic treatments over the last 30 years with a global sales revenue around $89 billion reported in 2017. A popular framework widely used in pharmaceutical industries for designing manufacturing processes for mAbs is Quality by Design (QbD) due to providing a structured and systematic approach in investigation and screening process parameters that might influence the product quality. However, due to the large number of product quality attributes (CQAs) and process parameters that exist in an mAb process platform, extensive investigation is needed to characterise their impact on the product quality which makes the process development costly and time consuming. There is thus an urgent need for methods and tools that can be used for early risk-based selection of critical product properties and process factors to reduce the number of potential factors that have to be investigated, thereby aiding in speeding up the process development and reduce costs. In this study, a framework for predictive model development based on Quantitative Structure- Activity Relationship (QSAR) modelling was developed to link structural features and properties of mAbs to Hydrophobic Interaction Chromatography (HIC) retention times and expressed mAb yield from HEK cells. Model development was based on a structured approach for incremental model refinement and evaluation that aided in increasing model performance until becoming acceptable in accordance to the OECD guidelines for QSAR models.
    [Show full text]
  • Classification Decisions Taken by the Harmonized System Committee from the 47Th to 60Th Sessions (2011
    CLASSIFICATION DECISIONS TAKEN BY THE HARMONIZED SYSTEM COMMITTEE FROM THE 47TH TO 60TH SESSIONS (2011 - 2018) WORLD CUSTOMS ORGANIZATION Rue du Marché 30 B-1210 Brussels Belgium November 2011 Copyright © 2011 World Customs Organization. All rights reserved. Requests and inquiries concerning translation, reproduction and adaptation rights should be addressed to [email protected]. D/2011/0448/25 The following list contains the classification decisions (other than those subject to a reservation) taken by the Harmonized System Committee ( 47th Session – March 2011) on specific products, together with their related Harmonized System code numbers and, in certain cases, the classification rationale. Advice Parties seeking to import or export merchandise covered by a decision are advised to verify the implementation of the decision by the importing or exporting country, as the case may be. HS codes Classification No Product description Classification considered rationale 1. Preparation, in the form of a powder, consisting of 92 % sugar, 6 % 2106.90 GRIs 1 and 6 black currant powder, anticaking agent, citric acid and black currant flavouring, put up for retail sale in 32-gram sachets, intended to be consumed as a beverage after mixing with hot water. 2. Vanutide cridificar (INN List 100). 3002.20 3. Certain INN products. Chapters 28, 29 (See “INN List 101” at the end of this publication.) and 30 4. Certain INN products. Chapters 13, 29 (See “INN List 102” at the end of this publication.) and 30 5. Certain INN products. Chapters 28, 29, (See “INN List 103” at the end of this publication.) 30, 35 and 39 6. Re-classification of INN products.
    [Show full text]
  • Targeting the Epidermal Growth Factor Receptor in EGFR-Mutated Lung Cancer: Current and Emerging Therapies
    cancers Review Targeting the Epidermal Growth Factor Receptor in EGFR-Mutated Lung Cancer: Current and Emerging Therapies Karam Khaddour 1,*, Sushma Jonna 1, Alexander Deneka 2 , Jyoti D. Patel 3, Mohamed E. Abazeed 4, Erica Golemis 2 , Hossein Borghaei 5 and Yanis Boumber 3,6,* 1 Division of Hematology and Oncology, University of Illinois at Chicago, Chicago, IL 60612, USA; [email protected] 2 Fox Chase Cancer Center, Program in Molecular Therapeutics, Philadelphia, PA 19111, USA; [email protected] (A.D.); [email protected] (E.G.) 3 Robert H. Lurie Comprehensive Cancer Center, Division of Hematology/Oncology, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA; [email protected] 4 Robert H. Lurie Comprehensive Cancer Center, Department of Radiation Oncology, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA; [email protected] 5 Fox Chase Cancer Center, Department of Hematology and Oncology, Philadelphia, PA 19111, USA; [email protected] 6 Institute of Fundamental Medicine and Biology, Kazan Federal University, 420008 Kazan, Russia * Correspondence: [email protected] (K.K.); [email protected] (Y.B.) Simple Summary: Epidermal growth factor receptor (EGFR) mutations occur in a significant number Citation: Khaddour, K.; Jonna, S.; of lung cancer patients. Treatment outcomes in this subset of patients has greatly improved over the Deneka, A.; Patel, J.D.; Abazeed, M.E.; last decade after the introduction of EGFR tyrosine kinase inhibitors (TKIs), which demonstrated high Golemis, E.; Borghaei, H.; Boumber, Y. efficacy and improved survival in randomized clinical trials. Although EGFR TKIs became the stan- Targeting the Epidermal Growth dard of care in patients with EGFR-mutated lung cancer, resistance almost inevitably develops.
    [Show full text]
  • Interim Report for the First Quarter of 2020
    Genmab Announces Financial Results for the First Quarter of 2020 May 6, 2020; Copenhagen, Denmark; Interim Report for the First Quarter Ended March 31, 2020 Highlights DARZALEX® (daratumumab) net sales increased approximately 49% compared to the first quarter of 2019 to USD 937 million, resulting in royalty income of DKK 775 million DARZALEX approved in Europe in combination with bortezomib, thalidomide and dexamethasone for the treatment of adult patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant U.S. FDA approved TEPEZZA™ (teprotumumab-trbw), developed and commercialized by Horizon Therapeutics, for thyroid eye disease U.S. FDA accepted, with priority review, Novartis’ supplemental Biologics License Application for subcutaneous ofatumumab in relapsing multiple sclerosis Anthony Pagano appointed Chief Financial Officer Anthony Mancini appointed Chief Operating Officer “Despite the unprecedented challenges posed by the coronavirus (COVID-19) pandemic, we will continue to invest in our innovative proprietary products, technologies and capabilities and use our world-class expertise in antibody drug development to create truly differentiated products with the potential to help cancer patients. While Genmab is closely monitoring the developments in the rapidly evolving landscape, we are extremely fortunate to have a solid financial foundation and a fabulous and committed team to carry us through these uncertain times,” said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab. Financial Performance First Quarter of 2020 Revenue was DKK 892 million in the first quarter of 2020 compared to DKK 591 million in the first quarter of 2019. The increase of DKK 301 million, or 51%, was mainly driven by higher DARZALEX royalties.
    [Show full text]
  • Evkeeza™ (Evinacumab-Dgnb) NOTICE
    DRUG POLICY Evkeeza™ (evinacumab-dgnb) NOTICE This policy contains information which is clinical in nature. The policy is not medical advice. The information in this policy is used by Wellmark to make determinations whether medical treatment is covered under the terms of a Wellmark member's health benefit plan. Physicians and other health care providers are responsible for medical advice and treatment. If you have specific health care needs, you should consult an appropriate health care professional. If you would like to request an accessible version of this document, please contact customer service at 800-524-9242. BENEFIT APPLICATION Benefit determinations are based on the applicable contract language in effect at the time the services were rendered. Exclusions, limitations or exceptions may apply. Benefits may vary based on contract, and individual member benefits must be verified. Wellmark determines medical necessity only if the benefit exists and no contract exclusions are applicable. This policy may not apply to FEP. Benefits are determined by the Federal Employee Program. DESCRIPTION The intent of the Evkeeza™ policy is to provide coverage consistent with product labeling, FDA guidance, standards of medical practice, evidence-based drug information, and/or published guidelines. The indications below including FDA-approved indications and compendial uses are considered covered benefits provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy. FDA-Approved Indications Evkeeza (evinacumab-dgnb) is an ANGPTL3 (angiopoietin-like 3) inhibitor indicated as an adjunct to other low-density lipoprotein-cholesterol (LDL-C) lowering therapies for the treatment of adult and pediatric patients, aged 12 years and older, with homozygous familial hypercholesterolemia (HoFH).
    [Show full text]
  • Therapies for EGFR-Mutated NSCLC Current Approvals and Indications1 Full Abbreviations, Accreditation, and Disclosure Information Available at Peerview.Com/CWE40
    Therapies for EGFR-Mutated NSCLC 1 Current Approvals and Indications Full abbreviations, accreditation, and disclosure information available at PeerView.com/CWE40 First-Generation Second-Generation Reversible EGFR TKIs Irreversible EGFR TKIs Getinib Erlotinib Afatinib Dacomitinib • 1L for EGFR exon 19 • 1L for EGFR exon 19 • 1L for EGFR exon 19 • 1L for EGFR exon 19 deletions or L858R, S768I, deletions or L858R deletions or L858R deletions or L858R L861Q, and/or G719X mutations mutations mutations mutations Metastatic Third-Generation EGFR TKI + VEGFR2 Irreversible EGFR TKI Antagonist Osimertinib Erlotinib + Ramucirumab • 1L for EGFR exon 19 deletions or L858R mutations • Treatment of T790M-positive NSCLC with progression • 1L for EGFR exon 19 deletions or L858R mutations on or after EGFR TKI therapy Early Stage Third-Generation Irreversible EGFR TKI • Adjuvant therapy after tumor resection in patients with stage IB-IIIA NSCLC whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations Osimertinib 1. https://www.fda.gov/drugs/resources-information-approved-drugs/hematologyoncology-cancer-approvals-safety-notifications. Molecular Testing Guidelines for NSCLC Latest Updates, Best Practices, and Patient-Reported Insights1 Full abbreviations, accreditation, and disclosure information available at PeerView.com/CWE40 Why Test Lung Cancer Patients for Genomic Alterations? • Genomic alterations are common in nonsquamous NSCLC (approximately 50%) • Targeted therapies produce better treatment outcomes (eg, higher response rates, improved
    [Show full text]
  • The Two Tontti Tudiul Lui Hi Ha Unit
    THETWO TONTTI USTUDIUL 20170267753A1 LUI HI HA UNIT ( 19) United States (12 ) Patent Application Publication (10 ) Pub. No. : US 2017 /0267753 A1 Ehrenpreis (43 ) Pub . Date : Sep . 21 , 2017 ( 54 ) COMBINATION THERAPY FOR (52 ) U .S . CI. CO - ADMINISTRATION OF MONOCLONAL CPC .. .. CO7K 16 / 241 ( 2013 .01 ) ; A61K 39 / 3955 ANTIBODIES ( 2013 .01 ) ; A61K 31 /4706 ( 2013 .01 ) ; A61K 31 / 165 ( 2013 .01 ) ; CO7K 2317 /21 (2013 . 01 ) ; (71 ) Applicant: Eli D Ehrenpreis , Skokie , IL (US ) CO7K 2317/ 24 ( 2013. 01 ) ; A61K 2039/ 505 ( 2013 .01 ) (72 ) Inventor : Eli D Ehrenpreis, Skokie , IL (US ) (57 ) ABSTRACT Disclosed are methods for enhancing the efficacy of mono (21 ) Appl. No. : 15 /605 ,212 clonal antibody therapy , which entails co - administering a therapeutic monoclonal antibody , or a functional fragment (22 ) Filed : May 25 , 2017 thereof, and an effective amount of colchicine or hydroxy chloroquine , or a combination thereof, to a patient in need Related U . S . Application Data thereof . Also disclosed are methods of prolonging or increasing the time a monoclonal antibody remains in the (63 ) Continuation - in - part of application No . 14 / 947 , 193 , circulation of a patient, which entails co - administering a filed on Nov. 20 , 2015 . therapeutic monoclonal antibody , or a functional fragment ( 60 ) Provisional application No . 62/ 082, 682 , filed on Nov . of the monoclonal antibody , and an effective amount of 21 , 2014 . colchicine or hydroxychloroquine , or a combination thereof, to a patient in need thereof, wherein the time themonoclonal antibody remains in the circulation ( e . g . , blood serum ) of the Publication Classification patient is increased relative to the same regimen of admin (51 ) Int .
    [Show full text]
  • Antibodies to Watch in 2021 Hélène Kaplona and Janice M
    MABS 2021, VOL. 13, NO. 1, e1860476 (34 pages) https://doi.org/10.1080/19420862.2020.1860476 PERSPECTIVE Antibodies to watch in 2021 Hélène Kaplona and Janice M. Reichert b aInstitut De Recherches Internationales Servier, Translational Medicine Department, Suresnes, France; bThe Antibody Society, Inc., Framingham, MA, USA ABSTRACT ARTICLE HISTORY In this 12th annual installment of the Antibodies to Watch article series, we discuss key events in antibody Received 1 December 2020 therapeutics development that occurred in 2020 and forecast events that might occur in 2021. The Accepted 1 December 2020 coronavirus disease 2019 (COVID-19) pandemic posed an array of challenges and opportunities to the KEYWORDS healthcare system in 2020, and it will continue to do so in 2021. Remarkably, by late November 2020, two Antibody therapeutics; anti-SARS-CoV antibody products, bamlanivimab and the casirivimab and imdevimab cocktail, were cancer; COVID-19; Food and authorized for emergency use by the US Food and Drug Administration (FDA) and the repurposed Drug Administration; antibodies levilimab and itolizumab had been registered for emergency use as treatments for COVID-19 European Medicines Agency; in Russia and India, respectively. Despite the pandemic, 10 antibody therapeutics had been granted the immune-mediated disorders; first approval in the US or EU in 2020, as of November, and 2 more (tanezumab and margetuximab) may Sars-CoV-2 be granted approvals in December 2020.* In addition, prolgolimab and olokizumab had been granted first approvals in Russia and cetuximab saratolacan sodium was first approved in Japan. The number of approvals in 2021 may set a record, as marketing applications for 16 investigational antibody therapeutics are already undergoing regulatory review by either the FDA or the European Medicines Agency.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2017/0172932 A1 Peyman (43) Pub
    US 20170172932A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2017/0172932 A1 Peyman (43) Pub. Date: Jun. 22, 2017 (54) EARLY CANCER DETECTION AND A 6LX 39/395 (2006.01) ENHANCED IMMUNOTHERAPY A61R 4I/00 (2006.01) (52) U.S. Cl. (71) Applicant: Gholam A. Peyman, Sun City, AZ CPC .......... A61K 9/50 (2013.01); A61K 39/39558 (US) (2013.01); A61K 4I/0052 (2013.01); A61 K 48/00 (2013.01); A61K 35/17 (2013.01); A61 K (72) Inventor: sham A. Peyman, Sun City, AZ 35/15 (2013.01); A61K 2035/124 (2013.01) (21) Appl. No.: 15/143,981 (57) ABSTRACT (22) Filed: May 2, 2016 A method of therapy for a tumor or other pathology by administering a combination of thermotherapy and immu Related U.S. Application Data notherapy optionally combined with gene delivery. The combination therapy beneficially treats the tumor and pre (63) Continuation-in-part of application No. 14/976,321, vents tumor recurrence, either locally or at a different site, by filed on Dec. 21, 2015. boosting the patient’s immune response both at the time or original therapy and/or for later therapy. With respect to Publication Classification gene delivery, the inventive method may be used in cancer (51) Int. Cl. therapy, but is not limited to such use; it will be appreciated A 6LX 9/50 (2006.01) that the inventive method may be used for gene delivery in A6 IK 35/5 (2006.01) general. The controlled and precise application of thermal A6 IK 4.8/00 (2006.01) energy enhances gene transfer to any cell, whether the cell A 6LX 35/7 (2006.01) is a neoplastic cell, a pre-neoplastic cell, or a normal cell.
    [Show full text]
  • International Nonproprietary Names for Pharmaceutical Substances (INN)
    pre-publication copy Recommended INN: List 74 International Nonproprietary Names for Pharmaceutical Substances (INN) RECOMMENDED International Nonproprietary Names: List 74 Notice is hereby given that, in accordance with paragraph 7 of the Procedure for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances [Off. Rec. Wld Health Org., 1955, 60, 3 (Resolution EB15.R7); 1969, 173, 10 (Resolution EB43.R9); Resolution EB115.R4 (EB115/2005/REC/1)], the following names are selected as Recommended International Nonproprietary Names. The inclusion of a name in the lists of Recommended International Nonproprietary Names does not imply any recommendation of the use of the substance in medicine or pharmacy. Lists of Proposed (1–109) and Recommended (1–70) International Nonproprietary Names can be found in Cumulative List No. 15, 2013 (available in CD-ROM only). Dénominations communes internationales des Substances pharmaceutiques (DCI) Dénominations communes internationales RECOMMANDÉES: Liste 74 Il est notifié que, conformément aux dispositions du paragraphe 7 de la Procédure à suivre en vue du choix de Dénominations communes internationales recommandées pour les Substances pharmaceutiques [Actes off. Org. mond. Santé, 1955, 60, 3 (résolution EB15.R7); 1969, 173, 10 (résolution EB43.R9); résolution EB115.R4 (EB115/2005/REC/1)] les dénominations ci-dessous sont choisies par l’Organisation mondiale de la Santé en tant que dénominations communes internationales recommandées. L’inclusion d’une dénomination dans les listes de DCI recommandées n’implique aucune recommandation en vue de l’utilisation de la substance correspondante en médecine ou en pharmacie. On trouvera d’autres listes de Dénominations communes internationales proposées (1–109) et recommandées (1–70) dans la Liste récapitulative No.
    [Show full text]
  • CHMP Agenda of the 19-22 April 2021 Meeting
    28 July 2021 EMA/CHMP/220334/2021 Corr.11 Human Medicines Division Committee for medicinal products for human use (CHMP) Agenda for the meeting on 19-22 April 2021 Chair: Harald Enzmann – Vice-Chair: Bruno Sepodes 19 April 2021, 09:00 – 19:30, virtual meeting/ room 1C 20 April 2021, 08:30 – 19:30, virtual meeting/ room 1C 21 April 2021, 08:30 – 19:30, virtual meeting/ room 1D 22 April 2021, 08:30 – 19:00, virtual meeting/ room 1C Disclaimers Some of the information contained in this agenda is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also vary during the course of the review. Additional details on some of these procedures will be published in the CHMP meeting highlights once the procedures are finalised and start of referrals will also be available. Of note, this agenda is a working document primarily designed for CHMP members and the work the Committee undertakes. Note on access to documents Some documents mentioned in the agenda cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to on- going procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006). 1 Correction in section 8.1.1 Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 An agency of the European Union © European Medicines Agency, 2021.
    [Show full text]